39.00
-0.66 (-1.66%)
| Penutupan Terdahulu | 39.66 |
| Jumlah Dagangan | 304,092 |
| Harga / Jualan (P/S) | 90.77 |
| Harga / Buku (P/B) | 4.58 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.82 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.74% |
| Nisbah Semasa (MRQ) | 31.01 |
| Aliran Tunai Operasi (OCF TTM) | -67.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.00 M |
| Pulangan Atas Aset (ROA TTM) | -22.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rapport Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.28% |
| % Dimiliki oleh Institusi | 105.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp V, Llc | 30 Jun 2026 | 6,280,525 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,904,408 |
| Johnson & Johnson | 30 Jun 2026 | 1,784,517 |
| Polar Capital Holdings Plc | 30 Jun 2026 | 1,608,514 |
| Trv Gp Vi, Llc | 30 Jun 2026 | 969,218 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CEESAY ABRAHAM | - | 46.09 | -8,210 | -378,399 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,210 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -378,399 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 46.09 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CEESAY ABRAHAM | Pegawai | 08 Sep 2026 | Jual automatik (-) | 8,210 | 46.09 | 378,399 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |